Skip to main content
Novartis Top Menu
  • Novartis.com
Novartis Foundation LOGO
    • About Us 
      • Board of Trustees 
        • Joerg Reinhardt, Ph.D. 
        • Ann Aerts, M.D. 
        • Dr. Jo Ivey Boufford 
        • Lutz Hegemann, M.D., Ph.D. 
        • John Kahan 
        • Prof. Peter Piot, M.D. 
      • Our partners 
      Ghana telemedicine employees About Us
    • Transforming population health 
      • CARDIO4Cities 
      • AI4BetterHearts 
      • AI4HealthyCities 
        • Broadband Commission Working Group on Digital and AI in Health 
      • HealthTech Innovation 
        • Brazil COVID-19 response 
        • AI4Leprosy 
      A group of children playing outside and learning about heart health in South Africa Transforming Population Health
    • Urban Population Health Toolkit 
      • Quality of care 
      • Ensure access 
      • Policy reform 
      • Leverage data and digital 
      • Intersectoral collaboration 
      • Ensure local ownership 
      Diabetes testing in Vietnam Urban Population Health Toolkit
    • Past programs 
      • Better Hearts Better Cities 
        • Community-based Hypertension Improvement Project (ComHIP) 
        • Communities for Healthy Hearts 
        • KaziBantu (Healthy Schools for Healthy Communities) 
      • Leprosy and malaria elimination 
        • The Leprosy Alert and Response Network System (LEARNS) 
        • Leprosy Post-Exposure Prophylaxis (LPEP) program 
        • Malaria Targeted Parasite Elimination Strategy 
      • Digital Health 
        • Ghana Telemedicine 
        • Telemedicine Toolkit 
        • Integrated e-Diagnostic Approach 

      Past Programs - Mega Menu

      Patient with hypertension in hospital in Ghana Past Programs
    • Media Center 
      • News Archive  
      • Media Library  
      • Stories 
      Family participating in Leprosy Post-Exposure Prophylaxis (LPEP) Program in Nepal Media Center
    Image of three women presenting LEARNS on their mobile phones Homepage
  1. Home
  2. Media Center
  3. Media Library
  4. Leprosy Post-exposure Prophylaxis with Single-dose Rifampicin (LPEP): An International Feasibility Programme

Leprosy Post-exposure Prophylaxis with Single-dose Rifampicin (LPEP): An International Feasibility Programme

Back to Previous Page
Image of document cover
Description

LPEP explored the feasibility of combining three key interventions against leprosy: tracing contacts newly diagnosed patients with leprosy; screening the traced contacts for leprosy; and administering SDR to eligible contacts.

Leprosy Post-exposure Prophylaxis with Single-dose Rifampicin (LPEP): An International Feasibility Programme (PDF 393.02 KB)

Related Items

  • Cover image of the article regarding the leprosy diagnostic test development
    Document
    lock
    Leprosy, Publication
    Leprosy Diagnostic Test Development As a Prerequisite Towards Elimination: Requirements from the User’s Perspective
  • Cover image of the article about screening and chemoprophylaxis among contacts of leprosy patients
    Document
    lock
    Leprosy, Publication
    An Innovative Approach to Screening and Chemoprophylaxis among Contacts of Leprosy Patients in Low Endemic Settings: Experiences from Cambodia
  • Cover picture of the publication regarding leprosy control in routine settings
    Document
    lock
    Leprosy, Publication
    Minimal Essential Data to Document Contact Tracing and Single Dose Rifampicin (SDR) for Leprosy Control in Routine Settings: A Practical Guide
  • Cover of 2018 - CorNTD - Innovations in Leprosy Prophylaxis - Current Evidence and Upcoming Trials
    Document
    lock
    Leprosy, Publication
    Innovations in Leprosy Prophylaxis: Current Evidence and Upcoming Trials

Novartis Foundation

Navigate Novartis Foundation
  • About Us
  • Transforming Population Health
  • Urban Population Health Toolkit
  • Past Programs
About the Novartis Foundation
  • Board of Trustees
  • Our Partners
Media Center
  • News Archive
  • Media Library
  • Our Stories
Footer Bottom
© 2023 Novartis Foundation
  • Terms of Use
  • Privacy Policy
  • Cookie Settings
  • Site Map
Novartis Site Directory
This site is intended for a global audience